(Reuters) -Shares in Valneva slumped around 25% on Monday after the French drugmaker said the United States Food and Drug ...

The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with ...

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

U.S. health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of "serious adverse events", the drug's French maker said on Monday.

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ ®, citing ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

Valneva shares dropped after it said it will no longer be able to sell its chikungunya vaccine in the U.S. after reports linked the vaccine to adverse effects. Shares trading in New York were nearly ...